Monopar Therapeutics Highlights Significant ALXN1840 Findings
Monopar Therapeutics Inc. (Nasdaq: MNPR), a promising clinical-stage biopharmaceutical company, has recently announced an exciting development in their ongoing efforts to address unmet medical needs among patients. The company is set to present groundbreaking data concerning the ALXN1840 (tiomolybdate choline) drug candidate, aimed at treating Wilson disease, during a prestigious late-breaker poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2025.
Significant Presentation at EASL Congress 2025
The EASL Congress is known for being one of the premier platforms for hepatology research, where leading experts gather to share their latest findings. This year, the congress will take place in Amsterdam, from May 7 to May 10, offering a unique opportunity for Monopar to showcase their latest research.
Being selected for a late-breaker presentation is a notable achievement, as it signifies the importance and relevance of the findings being shared. Late-breakers are reserved for the most recent and impactful research that could substantially influence the field. This is especially vital for clinical studies that are prospective in nature, enhancing the likelihood of significant contributions to medical understanding.
Details of the Late-Breaker Presentation
For those interested in the specifics of the presentation, here are the pertinent details:
- Title: Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline
- Abstract Number: LB25251
- Session: Late-breaker Posters
- Date and Time: Wednesday, May 7, 8:30 a.m. CET
- Presenter: Karl Heinz Weiss, M.D.
- Location: Amsterdam, Netherlands
The findings presented in this late-breaker session are anticipated to provide insights into the long-term efficacy and safety of ALXN1840, potentially offering hope to those affected by Wilson disease.
About Monopar Therapeutics Inc.
Monopar Therapeutics is not just focused on ALXN1840 for Wilson disease; the company has a diverse portfolio of clinical-stage projects aimed at tackling various medical challenges. Their radiopharmaceutical programs include MNPR-101-Zr, which is being explored for imaging advanced cancers, alongside MNPR-101-Lu and MNPR-101-Ac225, both of which are in various stages of development for treating advanced cancers.
The commitment of Monopar to advancing innovative therapies underscores their role in the biopharmaceutical landscape, indicating their potential to significantly impact patient care in oncology and hepatology.
Stay Updated
For those eager to learn more about Monopar’s research and therapeutic advancements, additional details regarding the poster presentation will be made available on their official website on May 7.
Additionally, staying connected through social media is a great way to receive real-time updates and insights. You can follow Monopar on X at @MonoparTx and visit their LinkedIn page for further news and developments.
Frequently Asked Questions
What is ALXN1840 used for?
ALXN1840 is a drug candidate being developed for the treatment of Wilson disease, a genetic disorder that causes copper accumulation in the body.
When will the EASL Congress take place?
The EASL Congress will be held in Amsterdam from May 7 to May 10.
How significant is a late-breaker presentation?
Late-breaker presentations are important as they showcase the most recent and impactful research findings, often influencing future studies and clinical practices.
What other programs does Monopar have besides ALXN1840?
Monopar is also developing radiopharmaceuticals, including MNPR-101-Zr for imaging advanced cancers, and MNPR-101-Lu and MNPR-101-Ac225 for cancer treatment.
How can I stay updated on Monopar's developments?
You can follow Monopar on X and LinkedIn to receive the latest updates on their research and corporate activities.
